Abstract
Neurofibromatosis Type 1 (NF1) is a common genetic disorder with a high prevalence of CNS abnormalities including tumors, mainly gliomas involving the optic pathway. Current methods of surveillance using clinical and MRI imaging protocols are not effective in selecting the patients who have tumors that are likely to cause progressive symptoms or undergo high grade transformation, both of which would benefit from early therapy. This chapter highlights the clinical utility of cerebral 18F-flurodeoxyglucose positron emission tomography in children with NF1 in determining optic pathway tumors that require treatment, identifying high grade transformation of gliomas and in differentiating MRI T2 weighted hyperintense lesions from true gliomas in this patient population with often challenging neuroimaging findings.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Balestri P, Lucignani G, Fois A, Magliani L, Calistri L, Grana C, Di Bartolo RM, Perani D, Fazio F (1994) Cerebral glucose metabolism in neurofibromatosis type 1 assessed with [18F]-2-fluoro-2-deoxy-D-glucose and PET. J Neurol Neurosurg Psychiatry 57:1479–1483
Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, McCluggage C, Plon SE (2004) Outcomes of systematic screening for optic pathway tumors in children with neurofibromatosis type 1. Am J Med Genet A 127A:224–229
Borgwardt L, Hojgaard L, Carstensen H, Laursen H, Nowak M, Thomsen C, Schmiegelow K (2005) Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol 23:3030–3037
Brenner DJ, Hall EJ (2007) Computed tomography – an increasing source of radiation exposure. N Engl J Med 357:2277–2284
Buchert R, von Borczyskowski D, Wilke F, Gronowsky M, Friedrich RE, Brenner W, Mester J, Clausen M, Mautner VF, Buchert R, von Borczyskowski D, Wilke F, Gronowsky M, Friedrich RE, Brenner W, Mester J, Clausen M, Mautner VF (2008) Reduced thalamic 18F-flurodeoxyglucose retention in adults with neurofibromatosis type 1. Nucl Med Commun 29:17–26
Chen W (2007) Clinical applications of PET in brain tumors. J Nucl Med 48:1468–1481
Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH (2005) Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46:945–952
Cohen BH, Rothner AD (1989) Incidence, types, and management of cancer in patients with neurofibromatosis. Oncology 3:23–30, discussion 34
Cohen BH, Kaplan AM, Packer RJ (1990) Management of intracranial neoplasms in children with neurofibromatosis type 1 and 2. The Children’s Cancer Study Group. Pediatr Neurosurg 16:66–72
DiPaolo DP, Zimmerman RA, Rorke LB, Zackai EH, Bilaniuk LT, Yachnis AT (1995) Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. Radiology 195:721–724
Fulham MJ, Melisi JW, Nishimiya J, Dwyer AJ, Di Chiro G (1993) Neuroimaging of juvenile pilocytic astrocytomas: an enigma. Radiology 189:221–225
Galldiks N, Kracht LW, Berthold F, Miletic H, Klein JC, Herholz K, Jacobs AH, Heiss WD (2010) [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol 96:231–239
Gill DS, Hyman SL, Steinberg A, North KN (2006) Age-related findings on MRI in neurofibromatosis type 1. Pediatr Radiol 36:1048–1056
Guillamo JS, Creange A, Kalifa C, Grill J, Rodriguez D, Doz F, Barbarot S, Zerah M, Sanson M, Bastuji-Garin S, Wolkenstein P (2003) Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 126:152–160
Hall EJ, Brenner DJ (2008) Cancer risks from diagnostic radiology. Br J Radiol 81:362–378
Hyman SL, Gill DS, Shores EA, Steinberg A, Joy P, Gibikote SV, North KN (2003) Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1. Neurology 60:1139–1145
Hyman SL, Shores A, North KN (2005) The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037–1044
Hyman SL, Gill DS, Shores EA, Steinberg A, North KN (2007) T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. J Neurol Neurosurg Psychiatry 78:1088–1091
Kaplan AM, Chen K, Lawson MA, Wodrich DL, Bonstelle CT, Reiman EM (1997) Positron emission tomography in children with neurofibromatosis-1. J Child Neurol 12:499–506
Kim G, Mehta M, Kucharczyk W, Blaser S (1998) Spontaneous regression of a tectal mass in neurofibromatosis 1. AJNR Am J Neuroradiol 19:1137–1139
Korf BR (2000) Malignancy in neurofibromatosis type 1. Oncologist 5:477–485
Leonard JR, Perry A, Rubin JB, King AA, Chicoine MR, Gutmann DH (2006) The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology 67:1509–1512
Listernick R, Charrow J, Greenwald MJ, Esterly NB (1989) Optic gliomas in children with neurofibromatosis type 1. J Pediatr 114:788–792
Listernick R, Charrow J, Greenwald M, Mets M (1994) Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 125:63–66
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109
Moharir M, London K, Howman-Giles R, North K (2010) Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1. Eur J Nucl Med Mol Imaging 37:1309–1317
Pirotte B, Acerbi F, Lubansu A, Goldman S, Brotchi J, Levivier M, Pirotte B, Acerbi F, Lubansu A, Goldman S, Brotchi J, Levivier M (2007) PET imaging in the surgical management of pediatric brain tumors. Childs Nerv Syst 23:739–751
Rosser T, Packer RJ (2002) Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol 17:630–637, discussion 646–651
Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC (2010) Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J AAPOS 14:155–158
Stumpf DA, Alksne JF, Annegers JF, Brown SS, Conneally PM, Housman D, Leppert MF, Miller JP, Moss ML, Pileggi AJ, Rapin I, Strohman RC, Swanson LW, Zimmerman A (1988) Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45:575–578
Sylvester CL, Drohan LA, Sergott RC (2006) Optic-nerve gliomas, chiasmal gliomas and neurofibromatosis type 1. Curr Opin Ophthalmol 17:7–11
Thiagalingam S, Flaherty M, Billson F, North K (2004) Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 111:568–577
Tripathi M, Sharma R, D’Souza M, Jaimini A, Panwar P, Varshney R, Datta A, Kumar N, Garg G, Singh D, Grover RK, Mishra AK, Mondal A (2009) Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med 34:878–883
Warren KE (2009) Noninvasive assessment of pediatric brain tumors. Cancer Biol Ther 8:1881–1888
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
London, K., Moharir, M., North, K., Howman-Giles, R. (2012). Children with Neurofi bromatosis Type 1: Positron Emission Tomography. In: Hayat, M. (eds) Pediatric Cancer, Volume 2. Pediatric Cancer, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2957-5_10
Download citation
DOI: https://doi.org/10.1007/978-94-007-2957-5_10
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-2956-8
Online ISBN: 978-94-007-2957-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)